Proteins



Product Data Sheet

Siglec-9 Protein, Human (HEK293, His)

Cat. No.: HY-P70739

Synonyms: Sialic acid-binding Ig-like lectin 9; Siglec-9; CDw329; Protein FOAP-9; SIGLEC9

Species: Human HEK293 Source:

AAH35365.2 (Q18-G348) Accession:

Gene ID: 27180 55-90 kDa Molecular Weight:

PROPERTIES

	_		
$\Lambda \Lambda$	Sea	HAN	00

HGWIYPGPVV QTSKLLTMQS SVTVQEGLCV HVPCSFSYPS HGYWFREGAN TDQDAPVATN NPARAVWEET RDRFHLLGDP HTKNCTLSIR DARRSDAGRY FFRMEKGSIK WNYKHHRLSV NVTALTHRPN ILIPGTLESG CPQNLTCSVP WACEQGTPPM ISWIGTSVSP LDPSTTRSSV LTLIPQPQDH GTSLTCQVTF PGASVTTNKT VHLNVSYPPQ NLTMTVFQGD GTVSTVLGNG SSLSLPEGQS LRLVCAVDAV DSNPPARLSL SWRGLTLCPS QPSNPGVLEL PWVHLRDAAE FTCRAQNPLG SQQVYLNVSL

QSKATSGVTQ

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.2 µm filtered solution of PBS, 2 mM EDTA, pH 7.4.

Endotoxin Level

<1 EU/µg, determined by LAL method.

Reconsititution

It is not recommended to reconstitute to a concentration less than $100 \, \mu g/mL$ in ddH_2O . For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

Sialic acid-binding immunoglobulin-like lectin (Siglec-9) is a member of the Siglec cell surface immunoglobulin family. Siglec-9 is highly expressed on human neutrophils and monocytes and low on natural killer cells, and sub-populations of T and B lymphocytes. Ligation of Siglec-9 by chemical compounds or synthetic ligands induced apoptosis and autophagic-like cell death in human neutrophils. Siglec-9 binds to sialic acid and transduces apoptotic and nonapoptotic death signals to neutrophils. Siglec-9 is an immune-checkpoint molecule on macrophages that can be targeted to enhance anti-PD-1/PD-L1 therapeutic efficacy for GBM treatment. Pro-tumorigenic activity can be suppressed by blocking Siglec-9, which unleashes antitumor functions and induces robust tumor-eliminating activity. Targeting Siglec-9 could be beneficial for the treatment of COPD, asthma, fibrosis, and related chronic inflammatory lung diseases^{[1][2][3]}.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com